The BiomarkerLIVE webinar series covers the foundational elements of biomarker testing and application in cancer care. Topics include biomarker basics, inherited cancers, cost and coverage, laboratory medicine, and tumor-specific case examples.

The Clinical Research Award recognizes individuals whose research has significantly and positively impacted the oncology patient, family, and/or community.

Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities? ​

With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.

Community cancer centers are fast becoming sites for biomarker testing and precision medicine. As clinical research becomes a larger part of community cancer center operations, strengthening tissue collection procedures and considering the establishment of biospecimen repositories are critical concerns.

A panel of hematologic malignancy experts provide important and practical information for the assessment of measurable residual disease (MRD) as part of routine clinical practice for their patients with chronic lymphocytic leukemia.

Tune into sessions from the ACCC Big Data in IO Workshop, where expert faculty will delve into role of data in managing immune-related adverse events; applications of clinical trial and real-world data; the evolving integration of molecular data and patient-reported outcomes; and how new technologies will impact the future of data in immuno-oncology.

In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.

In this educational webinar series, hear from experts in the field discuss the basics of PROs, how PROs can be integrated into IO clinical care, and how PROs can be used in IO clinical trials.

Organized around four case studies, the discussion will focus on current clinical evidence for optimal selection of immunotherapy and use of combination therapy. Topics covered include monitoring for and managing irAEs, care coordination and communication with non-oncology specialists, and assessment of institution- or practice-specific gaps in IO integration. Shared decision-making, toxicity management, reimbursement, and survivorship will also be discussed. This activity is supported by an educational grant from Bristol Myers Squibb.